...

Einstein Technologies (Cancer)

by user

on
1

views

Report

Comments

Transcript

Einstein Technologies (Cancer)
Einstein Technologies (Cancer)
Einstein
Reference
Number
Title of Patent
Application
Abstract
Senior Einstein
Investigator
Link to NonProvisional
Patent
Application
C-744
Inhibitors of saporin-L1 are disclosed, as are related compositions and
Saporin-L1 inhibitors and
uses thereof, in particular in cancer therapy that employs saporin-L1uses thereof
linked immunotoxins.
Vern Schramm
US 12/932,051
C-753
The present invention provides methods of preparing an
oligonucleotide, nucleoside or nucleoside analog for selective
introduction into a subject's cells, the method comprising (1)
selecting a targeted aptamer, internalizing nucleic acid or tumorhoming nucleic acid via iterative rounds of selection, and (i)
hybridizing it to an oligonuceotide, (ii) replacing one or more
nucleotide with a nucleoside or nucleoside analog, or (iii) synthesizing
the it with one or more nucleoside or nucleoside analogs; or (2)
preparing a naive combinatorial aptamer, internalizing nucleic acid or
tumor-homing nucleic acid prodrug library, and running iterative
rounds of selection for the cells. The present invention also provides
the agent, the pharmaceutical composition, and methods of treating
or preventing cancer and/or viral infection, the method comprising
administration of the oligonuleotide, nucleoside or nucleoside analog
for selective introduction into a subject's cells.
Matthew Levy
PCT/US11/00754
C-783
Compounds, compositions and methods are provided that comprise
selective β-glucuronidase inhibitors for both aerobic and anaerobic
bacteria, especially enteric bacteria normally associated with the
Selective betagastrointestinal tract. The compounds, compositions and methods
glucuronidase inhibitors
can be for inhibiting bacterial β-glucuronidases and for improving
as a treatment for side
efficacy of camptothecin-derived antineoplastic agents or
effects of camptothecin
glucuronidase-substrate agents or compounds by attenuating the side
antineoplastic agents
effects caused by reactivation by bacterial β-glucuronidases of
glucuronidated metabolites of camptothecin-derived antineoplastic
agents or glucuronidase-substrate agents or compounds.
Sridhar Mani
PCT/US2010/059690
C-797
Stat3 activation as a
Methods are disclosed for determining classification and prognosis of
marker for classification
patients with diffuse large B-cell lymphoma (DLBCL) using activation
and prognosis of dlbcl
of signal transducer and activator of transcription 3 (STAT3).
patients
B Hilda Ye
PCT/US2012/066782
C-800
Targets for diagnosis,
prognosis and therapy of Methods are disclosed for diagnosis, prognosis and therapy of acute
acute myeloid leukemia myeloid leukemia and myelodysplastic syndromes using interleukin 1
and myelodysplastic
receptor accessory protein and other targets.
syndromes
Ulrich Steidl
PCT/US2012/050062
C-801
A method of treating a tumor in a subject, or reducing or preventing
metastasis of a tumor in a subject, is provided comprising
administering to the subject an amount of a bacteria labelled with, or
comprising, one or more radionuclides so as to treat the tumor in the
subject, or so as to reduce or prevent metastasis of the tumor in the
subject. Radiobacteria-containing compositions and pharmaceutical
compositions are also provided.
Ekaterina
Dadachova
PCT/US2012/023785
C-812
Methods are provided for treating a cancer in a subject comprising
administering to the subject an agent which inhibits expression of an
Therapeutic and
HLX gene in the subject, or an agent which inhibits activity of an
diagnostic target gene in expression product of the HLX gene, and also for diagnosing a subject
acute myeloid leukemia as likely to develop a cancer comprising determining whether a stem
cell obtained from the subject expresses a HLX gene at a level in
excess of predetermined control level. Kits therefor are also provided.
Ulrich Steidl
PCT/US2012/036303
C-818
Myosin-iia s1943
phosphorylation as a
marker of tumor invasion
Anne Bresnick
13/419,805
Methods of preparing
targeted aptamer
prodrugs
Radiobacteria for
therapy of cancer
Methods and kits are provided for determining if cells of a tumor in an
organ or a tissue in a subject are likely to invade another organ or
tissue in the subject and for determining if a cancer in a subject is
likely to metastasize.
***Please note these technologies are representative of the Einstein Intellectual Property
Portfolio that are currently published patents/patent applications and available for licensing.
For non-published technologies please contact [email protected]
Version March 2016
Einstein Technologies (Cancer)
Abstract
Senior Einstein
Investigator
Link to NonProvisional
Patent
Application
Methods are disclosed for identifying activators and inhibitors of
actions of interleukin-34 (IL-34) that are independent of the colony
stimulating factor- 1 (CSF-1) receptor (CSF-1R) and play a role in
development, homeostasis and disease.
Evan R Stanley
PCT/US2014/38590
C-920
Macrophage-synthesized Methods and compositions are provided for inhibiting metastasis of a
ccl3 promotes breast tumor in a subject, or of inhibiting progression of a primary tumor in a
cancer metastasis
subject which requires macrophages for progression.
Jeffrey Pollard
13/860,109
C-963
Identification and use of
Methods are provided for diagnosing and treating a blood cancer or a
new tumor-promoting
myelodysplastic syndrome in a subject. Associated compositions and
gene in hematological
kits therefor are also provided.
malignancies
Ulrich Steidl
PCT/US2013/70227
C-976
Isolated polypeptides comprising a mutant programmed cell death 1
(PD-1) polypeptide and fusion polypeptides comprising an isolated
A selective high-affinity
mutant PD-1 polypeptide fused to an immunoglobulin domain
immune stimulatory
polypeptide are provided. Further provided are methods of using a
reagent and uses thereof
composition comprising the fusion polypeptide for stimulating T cell
activation for treating disorders including a tumor or an infection.
Steve Almo
PCT/US2014/15235
C-978
Small- molecule binding
site on pro-apoptotic bax Methods are provided for identifying an agent as a selective inhibitor
regulates inhibition of
of a Bcl-2-associated x-protein (BAX).
bax activity
Evripidis
Gavathoiotis
PCT/US2014/11213
Ulrich Steidl
PCT/US2014/24239
Einstein
Reference
Number
C-891
C-988
Title of Patent
Application
Il-34 receptor assays and
uses thereof
Pak1 inhibition for
treatment of acute
myeloid leukemia and
myelodysplastic
syndromes
Methods are disclosed for treating acute myeloid leukemia (AML) and
myelodysplastic syndromes (MDS) using inhibition of p21 protein
(Cdc42/Rac)-activated kinase (PAK1).
***Please note these technologies are representative of the Einstein Intellectual Property
Portfolio that are currently published patents/patent applications and available for licensing.
For non-published technologies please contact [email protected]
Version March 2016
Fly UP